Spotlight shifts—again—to anti-inflammatories for cutting CV risk

The National Institutes of Health and Novartis are investing in trials of drugs that inhibit the body's inflammatory response in the hope they will reduce cardiovascular adverse events and perhaps slow the progression of diabetes.

via The Heart